Autoimmune responses associated with SARS-CoV-2 infection
Autoimmune responses associated with SARS-CoV-2 infection
批准号:
10373287
负责人:
Sarah E. Wheeler
金额:
$22.29万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-19 至 2024-03-31
关键词:
2019-nCoVAcute Respiratory Distress SyndromeAffectAge-YearsAntibodiesAntibody ResponseAntigensAplastic AnemiaAppearanceAttentionAutoantibodiesAutoantigensAutoimmuneAutoimmune DiseasesAutoimmune ResponsesAutoimmunityBiological AssayCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCOVID-19COVID-19 pandemicCOVID-19 patientCell DeathCellsChildClinicalClinical ResearchComputerized Medical RecordCost SavingsDataDetectionDevelopmentDiabetes MellitusDiagnosisDiagnosticDiseaseDrug usageEpitope spreadingEpstein-Barr Virus InfectionsFDA approvedFutureGenderGenerationsGuillain Barré SyndromeHealthHealth Care CostsHealth ResourcesHuman Herpesvirus 4ImmuneImmune ToleranceImmune responseImmune systemImmunodiagnosticsImpairmentIndividualInfectionInsurance CarriersLaboratoriesLeadMeasuresMediatingMolecular MimicryMucocutaneous Lymph Node SyndromeMultiple SclerosisNuclear AntigensOutcomePathologyPathway interactionsPatientsPatternPeripheralPopulationPrevalencePreventionProcessPublic HealthQuality of lifeRecording of previous eventsRecoveryResearchRheumatoid ArthritisRiskRoleSARS-CoV-2 infectionSARS-CoV-2 infection historySamplingSelf ToleranceSerumSyndromeSystemic Lupus ErythematosusSystemic SclerodermaTestingTissuesVaccinesViralViral AntigensVirusVirus DiseasesVitiligoWorkage groupautoimmune rheumatologic diseasebiomarker identificationcase controlclinical carecohortcytokine release syndromediagnostic assayearly detection biomarkersfollow-uphealth care service utilizationhigh riskimmune activationlong term consequences of COVID-19post SARS-CoV-2 infectionpre-clinicalpreventresponsesample collectionsevere COVID-19side effectstandard of caresystemic autoimmune diseasesystemic inflammatory response
中文摘要
项目总结
目前的研究集中在新冠肺炎大流行的三个重要方面-治疗、疫苗和诊断。
指导UPMC临床免疫诊断实验室,我们了解启动临床的迫切需要
研究将使我们能够评估和分析康复人群中潜在的延迟健康结果
新冠肺炎患者。虽然强大的免疫反应与大多数SARS-CoV的临床恢复有关-
2感染患者,当保护性免疫反应受损或延迟时,病毒会传播,并大量
受影响的组织将被破坏。广泛的组织损伤和自身抗原的释放,特别是在
与不成比例的全身炎症和细胞因子风暴有关,已被证明调节失调
外周免疫耐受和促进自身免疫途径的启动。我们的工作假设是
新冠肺炎康复者发生自身抗原抗体的风险增加(S是高危人群)
风险假说具有重要的临床意义,将为未来的机制研究奠定基础。至
检验我们的假设,我们建议:确定自身抗体增加是否与先前的SARS-CoV相关-
2通过测量有新冠肺炎感染史的患者中自身抗体的患病率来确定感染情况。如果我们的
假设得到证实,我们的数据将提供第一个证据,证明需要跟随新冠肺炎找回
患者出现自身免疫抗体并增加全身和组织特异性风险
自身免疫性疾病。
英文摘要
PROJECT SUMMARY
Current research focuses on three important aspects of COVID-19 pandemic – therapy, vaccine and diagnostics.
Directing UPMC's Clinical Immune Diagnostic Laboratory, we understand the urgent need to initiate clinical
research that will allow us to assess and analyze potential deferred health outcomes in a population of recovered
COVID-19 patients. Although a robust immune response is associated with clinical recovery of most SARS-CoV-
2 infected patients, when a protective immune response is impaired or delayed, virus will propagate, and massive
destruction of the affected tissues will occur. Extensive tissue damage and release of autoantigens, especially if
associated with disproportionate systemic inflammation and cytokine storm, has been shown to dysregulate
peripheral immune tolerance and facilitate initiation of autoimmune pathways. Our working hypothesis that
COVID-19 recovered individuals are under increased risk of developing antibodies to self-antigen(s) is a high-
risk hypothesis with important clinical implications that will lay the groundwork for future mechanistic studies. To
test our hypothesis, we propose to: Determine if increased autoantibodies are associated with prior SARS-CoV-
2 infection by measuring prevalence of autoantibodies in patients with a history of COVID-19 infection. If our
hypothesis is confirmed, our data will provide the first evidence for the need to follow COVID-19 recovered
patients for the appearance of autoimmune antibodies and increased risk of systemic and tissue-specific
autoimmune diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autoimmune responses associated with SARS-CoV-2 infection
-
批准号:10611414
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2022
-
负责人:Sarah E. Wheeler
-
依托单位:
EGFRvIII expression, signaling and treatment in SCC of the head and neck
-
批准号:8100179
-
项目类别:
-
资助金额:$4.08万
-
财政年份:2010
-
负责人:Sarah E. Wheeler
-
依托单位:
EGFRvIII expression, signaling and treatment in SCC of the head and neck
-
批准号:8000381
-
项目类别:
-
资助金额:$4.22万
-
财政年份:2010
-
负责人:Sarah E. Wheeler
-
依托单位:
海外基金